The appendix is a tube-like structure, which is three to six inches long and is attached to the colon. It is situated in the lower right part of the abdomen. Appendiceal cancer or the cancer of the appendix is mostly found after the patients have surgery for acute appendicitis or when an abdominal mass is seen on a computerized tomography scan. The appendiceal cancer treatment market is expected to grow significantly over the forecast period.
Several factors such as a rise in targeted and innovative therapies confined to appendiceal cancer and increased awareness about the severity of the disease are anticipated to drive the growth of the market. According to the American Society of Clinical Oncology (ASCO), acute appendicitis is the most common cause in the US for an attack of severe, acute abdominal pain that requires an abdominal operation.
Additionally, in January 2018, GE Healthcare announced that it has entered into a long-term, strategic partnership with Roche Diagnostics to co-develop and market digital clinical decision support solutions. With this, the companies will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.
Appendix cancer usually does not cause symptoms until it is in an advanced stage and has spread to other parts of the body. Therefore, it becomes difficult to diagnose it in the right stage where corrective action can be taken. However, stringent government regulations about product approvals may hamper the market growth during the assessment period.
The appendiceal cancer treatment market has been segmented into type, treatment, and end-user.
The market, on the basis of type, has been segmented into neuroendocrine tumors and carcinomas.
The market, based on carcinomas, has been sub-segmented into mucinous adenocarcinoma, goblet cell carcinoids, intestinal-type adenocarcinoma, signet-ring cell adenocarcinoma, and paraganglioma.
The market, by treatment, has been segmented into surgery, chemotherapy, and radiation therapy.
The market, based on surgery, has been further segmented into appendectomy, hemicolectomy, and cytoreduction.
The market, based on chemotherapy, has been sub-segmented into hyperthermic intraperitoneal chemotherapy and systemic chemotherapy. The hyperthermic intraperitoneal chemotherapy segment is expected to be the largest segment due to its specificity to treat appendiceal cancer and also the high efficacy of drugs, whereas systemic chemotherapy is expected to be the fastest growing segment. This rapid growth is due to increasing awareness about the chemotherapeutic treatment and its increasing adoption rate by patients.
The market, by end-user, has been segmented into hospitals and clinics, cancer diagnostics and research institutes, and others.
AbbVie, Inc., Pfizer Inc., Eli Lilly & Company, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd., Becton, Dickinson & Company, Novartis AG, General Electric Company, AstraZeneca, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Sanofi, Bayer AG, Amgen Inc., and Merck are some of the key players in the appendiceal cancer treatment market.
Regional Market Summary
Global Appendiceal Cancer Treatment Market Share (%), by Region, 2017
Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The appendiceal cancer treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European appendiceal cancer treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The appendiceal cancer treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East and Africa has been segmented into the Middle East and Africa.
Geographically, the Americas is anticipated to dominate the global appendiceal cancer treatment owing to favorable reimbursement scenario and focus of the government on growing number of rare cancers. According to the American Cancer Society, it affects less than 1000 people each year and accounts for about five percent of all gastrointestinal cancers in the US.
Europe is expected to hold the second largest position in the appendiceal cancer treatment market. The market growth in this region is attributed to the growing prevalence of cancers and increasing healthcare expenditure.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cancer cases in China in 2015.
On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to a well-developed healthcare sector and growth initiatives by private healthcare companies.
Appendiceal cancer treatment market, by Type
Appendiceal cancer treatment market, by Treatment
Appendiceal cancer treatment market, by End-User
Appendiceal cancer treatment market, by Region
The Appendiceal Cancer Treatment Market would be restrained by strict government regulations regarding product approvals.
Factors like innovation in products and better awareness would drive Appendiceal Cancer Treatment Market ahead.
Types included in the Appendiceal Cancer Treatment Market are neuroendocrine tumors and carcinomas.
The treatments are surgery, chemotherapy, and radiation therapy included in the discussion of Appendiceal Cancer Treatment Market report.
Appendectomy, cytoreduction, and hemicolectomy are surgery types included in Appendiceal Cancer Treatment Market report